Gefticip-Gefitinib, Gefitinib (ZD1839) (INN, trade name Iressa, marketed by AstraZeneca and Teva), is a drug used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR.

Gefticip-Gefitinib 250 mg tablets Mechanism of action for Anti-cancer

Gefticip-Gefitinib

Medivac international are the leading suppliers Dealers Exporters Wholesalers of gefitinib. Gefitinib is the first selective inhibitor of epidermal growth factor receptor‘s (EGFR) tyrosine kinase domain. Thus gefitinib is an EGFR inhibitor. The target protein (EGFR) is a family of receptors which includes Her1(erb-B1), Her2(erb-B2), and Her 3(erb-B3). EGFR is overexpressed in the cells of certain types of human carcinomas – for example in lung and breast cancers. This leads to inappropriate activation of the anti-apoptotic Ras signalling cascade, eventually leading to uncontrolled cell proliferation. Research on gefitinib-sensitive non-small cell lung cancers has shown that a mutation in the EGFR tyrosine kinase domain is responsible for activating anti-apoptotic pathways.  These mutations tend to confer increased sensitivity to tyrosine kinase inhibitors such as gefitinib and erlotinib. Of the types of non-small cell lung cancer histologies, adenocarcinoma is the type that most often harbors these mutations. These mutations are more commonly seen in Asians, women, and non-smokers (who also tend to more often have adenocarcinoma).

Price of Gefticip-Gefitinib Tablet 250 mg Delhi India

Gefticip-Gefitinib inhibits EGFR tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the anti-apoptotic Ras signal transduction cascade is inhibited, and malignant cells are inhibited.

INDICATION:

Gefticip is used for the treatment of non-small cell lung cancer.

AVAILABLE AS:

250 mg tablets.

MANUFACTURE BY:

Cipla Ltd. (INDIA)

Brief Description and Cost of Gefticip-Gefitinib

DRUG CLASS AND MECHANISM: Gefitinib is a drug that is used to treat several types of lung cancer. It works by preventing lung cancer cells from growing and multiplying. Many cells, including cancer cells, have receptors on their surfaces for epidermal growth factor (EGF), a protein that is normally produced by the body and that promotes the growth and multiplication of cells. When EGF attaches to epidermal growth factor receptors (EGFRs), it causes an enzyme called tyrosine kinase to become active within the cells. Tyrosine kinase triggers chemical processes that cause the cells, including cancer cells, to grow, multiply, and spread. Gefitinib attaches to EGFRs and thereby blocks the attachment of EGF and the activation of tyrosine kinase. This mechanism for stopping cancer cells from growing and multiplying is very different from the mechanisms of chemotherapy and hormonal therapy. Gefitinib was approved by the FDA in May 2003.

Your enquiry to Find Gefticip-Gefitinib Suppliers Dealers manufacturers Wholesalers

Cost of Gefticip-Gefitinib in Australia, Brazil, China, Canada, Eqypt, Europe, France, Germany, Hongkong, India, Iran, Italy, Mexico, Pakistan, Poland, Spain, Singapore, Thailand, Russia, Romania, UK, Middle East, UAE, Ukraine.  Vietnam, Indonesia, Malaysia, South Korea, USA, London, Tajikistan, Uzbekistan, South Africa, China, Japan, Italy,  New Zealand, Srilanka.

Summary  for Gefticip Gefitinib

Medivac international are the leading of Gefticip Gefitinib Cipla Exporter, Distributor, Supplier, Trading Company, Delhi, India.We are the wholesale dealers of Gefticip tablets available as 250mg.